Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, announced Monday a lease agreement that will double the footprint at its Warren headquarters to about 13,000 square feet. Financial terms were not disclosed.
The expanded space will centralize cross-functional teams, including executive leadership, regulatory affairs, corporate strategy, and research and development, which was previously located in Philadelphia. The extra space is intended to increase operational efficiency and cross-team collaboration.
The headquarters will also house Tevogen.AITM and the Generics & Biosimilars initiative, with dedicated facilities for Tevogen.AI’s growing team of data scientists and engineers, as development of its proprietary AdapTcellTM and PredicTcellTM algorithms accelerates, strengthened by its partnership with Microsoft.
Tevogen has been in Warren for more than five years and has chosen Warren for its proximity to established life science infrastructure, access to top-tier talent and its business-oriented environment.
In addition to these core initiatives, the expanded facility could provide capacity to support potential new business units as Tevogen continues to grow and diversify its portfolio. The current number of full-time employees at Tevogen as of June 2025 is 19.
“This expansion will provide the infrastructure needed to support two of our evolving initiatives, Tevogen.AI and Generics & Biosimilars,” said Ryan Saadi, chief executive officer of Tevogen Bio. “From advancing domestic pharmaceutical manufacturing to harnessing the power of AI in drug discovery, these programs reflect our commitment to building a more resilient and accessible healthcare system.”
The newly leased space was formerly occupied by CAPTRUST, a national investment advisory firm. The building is owned by Mitsui Sumitomo Insurance Company of America, and parent company MS&AD Insurance Group Holdings Inc.
“We are proud to see Tevogen expand its footprint here in Warren,” said Warren Mayor Lisa Lontai. “This expansion is a testament to the groundbreaking innovation happening right here in Warren, and we are proud to be the home of such an innovative company”.
Tevogen was founded as a biotech company, Tevogen has plans to evolve into a multifaceted operation: Tevogen Bio, Tevogen.AI, and Tevogen Generics & Biosimilars.
Tevogen Bio shares were down 0.05, or 3.9%, to $1.38, in early trading. The stock has risen 37% this year. Tevogen has a market cap of $259.3 million.
